Collaboration with Boehringer Ingelheim on the project dedicated to central nervous system diseases

Intelliseq has been partnering with Boehringer Ingelheim Pharma GmbH & Co KG on a project dedicated to central nervous system diseases.

The long-range goal of the study was to verify the usability of the Fkbp5 × ELA (early life adversity) mouse model for further investigation of the Fkbp5 gene variants influence on the resilience to stress. Single nucleotide polymorphisms (SNPs) in the human FKBP5 gene were previously shown to modulate the risk of stress-related disorders.

To enable investigation of disease-related SNPs in a behaviorally relevant context, humanized mouse lines carrying either the risk (AT) or the resiliency (CG) allele of the rs1360780 locus were generated and exposed to maternal separation.

Intelliseq was responsible for library preparation, sequencing, and bioinformatic analysis of RNA-seq samples.

The results of the study showed that in combination with severe or chronic stress exposure, the observed Fkbp5 × ELA interactions likely contribute to the etiology of stress-related pathology.

Read the full study here

<h2>Want to know more?</h2>

Want to know more?

Get in touch with us.